Sponsored by:

Crown Bioscience

Beyond Checkpoints: Strategic Use of CDX Models in Emerging IO Therapies

Watch Now
Date:
September 30, 2025
Time (ET):
11:00 AM
Register Now
Crown Bioscience

Learn how enhanced CDX models with humanized immune systems improve preclinical-to-clinical success in emerging immuno-oncology therapies.

Cell line derived xenograft (CDX) models provide key decision-making information to allow an agent to move forward, and clients to advance their preclinical development programs in a timely and cost-effective manner.

Join us for this expert-led webinar where we will explore state-of-the-art methods to enhance CDX models by integrating a complete Tumor Microenvironment (TME) and humanizing the immune system. Discover breakthrough strategies that bridge the gap between preclinical studies and clinical applications, ensuring more reliable and actionable insights for immuno-oncology (IO) therapies.

Featuring Insights from

Kiel Peck

,

PhD

Crown Bioscience
Director, Scientific Operations - San Diego
Dr. Peck is a highly trained and experienced biologist specializing in drug discovery, development, and translational medicine. He received his PhD in Biomedical Sciences and Translational Medicine from Cedars-Sinai Medical Center in Los Angeles, California, under the guidance of the renowned cardiologist Dr. Eduardo Marban.

Prior to joining Crown Bioscience, Kiel worked extensively with small and medium-sized biotech companies to develop and advance their pre-clinical and IND-enabling drug discovery programs. Focusing mainly on product development and process optimization, he has shared multiple patents for novel manufacturing and bioengineering processes related to this work. He has successfully guided multiple drug discovery programs through the pre-IND process and onto successful IND filings. Kiel’s knowledge and experience in the early drug development pipeline provide him with the expertise and perspective to share with Crown Bioscience clients and collaborators.

Dr. Peck’s background in translational medicine positions him well to collaborate with Crown Bioscience clients as they advance their own programs through the rigors of science and regulatory approval. Kiel’s role at Crown Bioscience is to provide our clients with the knowledge and experience needed to help design and execute studies laser-focused on advancing their drug development platforms, regardless of their stage. From proof-of-concept and dose-finding studies through safety toxicology, biodistribution, and on to full efficacy studies. Kiel has experience in a wide range of critical IND-enabling studies that are foundational to the development and progression of new drug candidates.
Read More

Sponsored by

Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world’s largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience’s expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in vitro, ex vivo, and in silico methods, along with advanced laboratory services that span the entire drug development timeline. Additionally, it maintains an extensive biobank of liquid and human biospecimens, complete with clinical histories. Operating from 11 facilities in the US, Europe, and APAC—including laboratories accredited by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO)—Crown Bioscience upholds the highest standards of quality and reliability in its research environments.

In Partnership with

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

Related Content

Related Content